Standard Contracts
AGREEMENT BETWEEN: ADAPTIMMUNE LIMITED (1) and UNIVERSAL CELLS, INC. (2)Research Collaboration and License Agreement • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • England
Contract Type FiledMarch 17th, 2016 Company Industry JurisdictionThis RESEARCH COLLABORATION AND LICENCE AGREEMENT (the “Agreement”) is made as of the 25th day of November 2015 (the “Effective Date”) by and between:
ContractAmendment Agreement No. 2 • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledMarch 17th, 2016 Company Industry***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.
NON-EXCLUSIVE SUB-LICENSE AGREEMENTNon-Exclusive Sub-License Agreement • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Washington
Contract Type FiledMarch 17th, 2016 Company Industry JurisdictionTHIS AGREEMENT (“Agreement”) is dated and effective as of the date of last signature (“Effective Date”), and is made by and between Universal and Adaptimmune Limited, an English Adaptimmune with principal offices at 101 Park Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY (“Adaptimmune”), and Universal Cells, a Corporation under the laws of the state of Washington (“Universal”) with principal offices at 720 Broadway, Seattle, WA 98122, agree as follows:
ContractHla/Aav Sublicence • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances) • Washington
Contract Type FiledMarch 17th, 2016 Company Industry Jurisdiction***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.
ContractAmendment Agreement • March 17th, 2016 • Adaptimmune Therapeutics PLC • Biological products, (no disgnostic substances)
Contract Type FiledMarch 17th, 2016 Company Industry***Certain portions of this exhibit have been omitted based on a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. The omitted portions have been filed separately with the Securities and Exchange Commission.